Valuation : Daxor Corporation

Market Cap 59.96M 51.64M 48.57M 44.37M 82.95M 5.66B 83.23M 573M 222M 2.9B 225M 220M 9.37B P/E 2026 *
-48.9x
P/E 2027 * -342x
Enterprise Value 59.96M 51.64M 48.57M 44.37M 82.95M 5.66B 83.23M 573M 222M 2.9B 225M 220M 9.37B EV / Sales 2026 *
6.45x
EV / Sales 2027 * 3.66x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 day-2.66%
1 week+0.69%
Current month+1.89%
1 month-2.00%
3 months-3.11%
6 months-10.31%
Current year-30.37%
1 week 9.9
Extreme 9.9001
11.11
1 month 9.55
Extreme 9.5501
11.11
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/28/26 Free

Chief Technology Officer

2,451 0.0420%
6/23/26 Free

Director

2,500 0.0429%
4/8/26 Buy

Chief Executive Officer

1,000 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
-2.66%+0.69%-7.14%+2.91% 59.96M
-0.83%-0.59%+21.74%+123.85% 15.94B
-1.18%-0.64%+56.57%+169.57% 13.71B
-0.41%-1.07%-12.04%+28.91% 9.16B
-1.11%-0.59%+35.54%+148.74% 7.94B
+0.26%0.00%-23.46%-15.49% 7.08B
-0.79%-2.34%+7.49%+34.83% 6.86B
+0.64%-1.26%+10.00%+28.88% 4.87B
-0.09%-1.74%+9.04%+8.05% 4.05B
-0.69%-1.09% - - 3.9B
Average -0.69%-0.74%+10.86%+58.92% 7.36B
Weighted average by Cap. -0.62%-0.90%+18.15%+86.81%

Financials

2026 *2027 *
Net sales 9.3M 8.01M 7.53M 6.88M 12.87M 879M 12.91M 88.9M 34.5M 450M 34.92M 34.16M 1.45B 16.4M 14.12M 13.28M 12.13M 22.69M 1.55B 22.76M 157M 60.84M 794M 61.58M 60.23M 2.56B
Net income -1.2M -1.03M -972K -888K -1.66M -113M -1.67M -11.47M -4.45M -58.08M -4.51M -4.41M -187M -200K -172K -162K -148K -277K -18.9M -278K -1.91M -742K -9.68M -751K -735K -31.25M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
26-09-04 US$10.27 -2.66% 6,791
26-09-03 US$10.55 -1.77% 51,551
26-09-02 US$10.74 -1.47% 25,765
26-09-01 US$10.90 +8.14% 24,451
26-08-31 US$10.08 -1.18% 872
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.27USD
Average target price
20.00USD
Spread / Average Target
+94.74%

Quarterly revenue - Rate of surprise